Preliminary results 2021 of Sartorius Stedim Biotech

Author's Avatar
Jan 31, 2022

- Sales revenue up 52.6 percent to 2,887 million euros; underlying EBITDA margin at 35.8 percent, up from 31.7 percent a year ago

- Dynamic and profitable organic growth; pandemic-related demand as well as excellent development of acquisitions

- Number of employees rises by around 38 percent to more than 10,400

- Outlook for 2022: Sales revenue to increase by 14 percent to 18 percent with sustained high profitability

- Mid-term targets until 2025: Management confirms revenue target of 4 billion euros and raises profitability target to more than 35 percent

- Ambitious target set for continuous reduction of CO2 emission intensity

PR Newswire